CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
Hoofdauteurs: | , , , , , , , , , , |
---|---|
Formaat: | Conference item |
Taal: | English |
Gepubliceerd in: |
Wiley
2022
|